India, March 21 -- TC BioPharm (Holdings) PLC (TCBP) has been ordered to delist from Nasdaq due to non-compliance with the minimum $1.00 bid price requirement under Nasdaq Rule 5550(a)(2).
The company received notice from the Nasdaq Hearings Panel on March 20, 2025, and is currently appealing the decision.
Trading of TC BioPharm's securities on Nasdaq will be suspended starting March 24, 2025. However, its American Depositary Shares - ADSs are expected to trade on the OTC Markets from the same date. The company will continue to file reports with the SEC as required under federal securities laws.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Despite the delisting, TC BioPharm remains committed to it...